Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Abcellera Biologics Inc ABCL

Healthcare Biotechnology
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for... see more

Recent & Breaking News (NDAQ:ABCL)

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Business Wire November 10, 2025

AbCellera Reports Q3 2025 Business Results

Business Wire November 6, 2025

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Business Wire October 7, 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Business Wire September 29, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Business Wire September 10, 2025

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Business Wire August 27, 2025

AbCellera to Participate at Upcoming Investor Conferences in September

Business Wire August 12, 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Business Wire August 7, 2025

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Business Wire July 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

Business Wire May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

Business Wire May 14, 2025

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

Business Wire May 12, 2025

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

Business Wire May 9, 2025

AbCellera Reports Q1 2025 Business Results

Business Wire May 8, 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Business Wire April 29, 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Business Wire April 8, 2025

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Business Wire April 3, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Business Wire March 25, 2025

AbCellera Reports Full Year 2024 Business Results

Business Wire February 27, 2025

AbCellera to Participate at Upcoming Investor Conferences in March

Business Wire February 11, 2025